Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil

Cassia F Estofolete; Cecilia A Banho; Guilherme R F Campos; Beatriz de C Marques; Livia Sacchetto; Leila S Ullmann; Fabio S Possebon; Luana F Machado; Juliana D Syrio; João P Araújo Junior; Cintia Bittar; Paula Rahal; Suzana M A Lobo; Helena Lage Ferreira; Nikos Vasilakis; Mauricio L Nogueira

doi:10.3390/v13071237

Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil

Viruses. 2021 Jun 26;13(7):1237. doi: 10.3390/v13071237.

Authors

Cassia F Estofolete^{1

2}, Cecilia A Banho¹, Guilherme R F Campos¹, Beatriz de C Marques¹, Livia Sacchetto¹, Leila S Ullmann³, Fabio S Possebon³, Luana F Machado², Juliana D Syrio², João P Araújo Junior³, Cintia Bittar⁴, Paula Rahal⁴, Suzana M A Lobo², Helena Lage Ferreira⁵, Nikos Vasilakis^{6

7

8

9

10}, Mauricio L Nogueira^{1

2}

Affiliations

¹ Laboratório de Pesquisas em Virologia (LPV), Medicine School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo 15090-000, Brazil.
² Hospital de Base, São José do Rio Preto, São Paulo 15090-000, Brazil.
³ Biotecnology Institute, São Paulo State University (UNESP), Botucatu, São Paulo 18607-440, Brazil.
⁴ Intitute of Biosciences, Languages and Exact Sciences, São Paulo State University (UNESP), São José do Rio Preto, São Paulo 15054-000, Brazil.
⁵ Department of Veterinary Medicine FZEA-USP, University of São Paulo (USP), Pirassununga, São Paulo 13635-900, Brazil.
⁶ Department of Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.
⁷ Sealy Center for Vector-Borne and Zoonotic Diseases, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.
⁸ Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.
⁹ Center for Tropical Diseases, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.
¹⁰ Institute for Human Infection and Immunity, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA.

Abstract

The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.

Keywords: COVID-19; SARS-CoV-2; vaccine.

Publication types

Case Reports
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral / blood*
Brazil
COVID-19 / diagnostic imaging*
COVID-19 / immunology*
COVID-19 / prevention & control
COVID-19 Drug Treatment
COVID-19 Nucleic Acid Testing
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / immunology*
Clinical Trials as Topic
Dexamethasone / therapeutic use
Humans
Male
Middle Aged
SARS-CoV-2 / genetics
SARS-CoV-2 / immunology*
Severity of Illness Index
Tomography, X-Ray Computed
Treatment Outcome
Vaccination / adverse effects*
Vaccination / statistics & numerical data

Substances

Antibodies, Viral
COVID-19 Vaccines
Dexamethasone

Grants and funding

U01 AI151807/NH/NIH HHS/United States